TeleVox

A communications and delivery business with a conversational layer on top, and the company is reasonably precise about which is which. The core asset built over decades is the ability to reach patients reliably at scale across text, voice, email and physical mail, together with the workflow content of reminders, recalls, bill pay and refill prompts. That is logistics and clinical content design rather than a model.

The artificial intelligence lives in a named product, Engage, which supplies conversational responses and self service handling and escalates to a person when it cannot proceed. Crediting the precision matters here: the company names the conversational product rather than relabelling the whole platform as artificial intelligence, which is the restraint this index credited to TheraDoc and marked down where others did the opposite. This is the same incumbent shape recorded several times across this session, where a business that predates the current wave adds a model to a distribution position it already held.

Bounded and stated. The conversational product answers patient inquiries, manages appointments and handles routine transactions, and the company describes seamless escalation to live chat as part of the design rather than as an afterthought, so the handoff to a human is a published feature. Nothing clinical is decided.

What is not described anywhere located is the escalation criterion, the handling of a patient who raises a clinical concern during a billing or scheduling conversation, or whether patients are told they are corresponding with a machine, and the last is worth asking of any product operating across text and voice at this scale.

Two retrieval passes located no architecture, no model description, no validation methodology and no accuracy figure. The phrase carrying the technical claim is conversational artificial intelligence, which specifies nothing. One published claim deserves particular scrutiny and is graded on the governance row: company material states that a patient can write in their own language and the system will translate it for the clinician with great accuracy, which is an accuracy claim about clinical translation offered without any evidence.

Two passes located no named customer, no case study identifying an organisation, no peer reviewed publication and no independent evaluation. That is a striking absence for a business of this age and reach, and it likely reflects a company that has never needed to publish because it sells into procurement processes rather than clinical ones.

A revenue figure circulates in a commercial database, but it appears in a summary that database itself labels as machine generated and possibly inaccurate, so it is not relied on here. Nothing located establishes what the conversational product achieves relative to the reminder infrastructure the company already had.

The substantive material found belongs to a former parent and is a decade old, which is a distinction this index has had to draw before. Securities filings from the corporate owner in the 2011 to 2014 period describe HIPAA and health information technology compliance training for healthcare services staff, acknowledge business associate status, and record ongoing data security testing and physical security review at healthcare operation centres.

That is a more explicit account than most vendors publish. It is also not TeleVox's own current statement, it predates two changes of ownership, and no present day retention, minimisation or secondary use position for this product was located. Graded on that basis, and it is the same parent versus product distinction recorded against VigiLanz.

A former parent's filings state plainly that the business is sometimes considered a business associate under HIPAA and must protect the security and privacy of protected health information supplied by clients, which is a clearer acknowledgement of the legal position than most vendors in this index offer anywhere.

The qualifications are the same as on the stewardship row: it is a decade old, it belongs to a corporate parent that has since changed twice, and no current agreement terms, privacy page or subprocessor list for TeleVox itself was located. A buyer should ask for present day documentation rather than relying on the historical record, particularly given the unresolved ownership position.

Two passes located no SOC 2, no HITRUST, no ISO 27001, no trust centre and no vulnerability disclosure policy for this product. A competing vendor's comparison page asserts its own certification while attributing none to TeleVox, and that is a self interested source and is not graded on in either direction, consistent with how this index handles vendor authored competitive content.

For a supplier transmitting patient communication at national scale, and one whose corporate lineage runs through a regulated telecommunications carrier, published attestation would be expected and none was found.

No clearance, authorisation or submission located and none needed. Reminders, scheduling, billing prompts and refill notices are administrative. The regulatory frame that matters is telecommunications rather than device law, since automated outbound contact with patients falls under telephone consumer protection rules that turn on the consent a patient gave to be contacted automatically, and that exposure grows rather than shrinks as a reminder becomes a conversation.

The corporate lineage is unusual in that respect: the former parent was itself a regulated carrier and an emergency services provider, so the organisation has institutional familiarity with communications regulation that most healthcare software vendors lack.

Nothing published, and one specific claim raises a risk the company does not appear to have assessed. Company material states that a patient can write a message in their native language and the system will translate it for their doctor with great accuracy.

Machine translation of clinical communication is a documented source of harm, because errors are not random: they cluster in exactly the constructions patients use to describe symptoms, negation and dosage, and a fluent wrong translation carries no signal that it is wrong. Claiming great accuracy without publishing a measurement, a language list or a human review requirement is the strongest unsupported claim located on this record.

Speech and language performance variation across accent, dialect and first language applies here as it has to eight prior records in this index, and no subgroup analysis, model card or drift monitoring was located.

Integration is central to the pitch and unevidenced in the particulars. The enterprise product is described as unifying the call centre, the record system, the customer relationship system and other digital health applications into one channel to the patient, and the company states that built in integrations drive scheduling, reminder and billing messages without staff intervention, which is the right design and is the reason a delivery platform becomes useful rather than merely noisy. Two passes located no named record system, no interoperability standard and no implementation detail. Graded C on what is verifiable rather than on the strength of the description.

Two passes located no architecture description, hosting region, residency commitment or deployment option. A hosted service is implied by the nature of an outbound messaging platform, and nothing beyond that inference is published. For a supplier transmitting patient communication across text, voice, email and physical mail, the question of where message content and patient contact data are held, and for how long after a message is sent, is basic and unanswered.

No pricing, pricing mechanism or basis of charge published, with third party coverage recording only that quotes are custom. The more consequential commercial fact concerns the supplier rather than the price. The business has passed through a corporate acquisition in 2007, a corporate rebranding, a private equity take private in 2017, a further group renaming, and in February 2024 its owner appointed banks to explore selling TeleVox specifically.

That process appears not to have resulted in a sale. Current material from a sibling brand states that the president of WestCX oversees both the Mosaicx and TeleVox brands within West Technology Group, having joined in 2025, which indicates TeleVox was retained and grouped with a sibling conversational artificial intelligence product rather than divested.

No announcement confirming the outcome was located, so the position is inferred from the sibling's own material rather than stated by the owner. A health system contracting here should still establish who the contracting entity is, what happens to agreements on a change of control, and where patient data sits through any future transaction, because a business that has been through four ownership or structural changes and one abandoned sale process is more likely than most to go through another.

Broad across organisation type, channel and function, which is what a delivery platform accumulates over decades. Customers span hospitals and health systems, medical practices, and dental and vision practices, which is a wider range of buyer size than most vendors in this index serve.

Channels cover text, voice, email and physical mail, and retaining postal delivery is not a legacy oddity but a genuine reach advantage for older and rural populations that digital only platforms miss entirely. Functionally it runs from appointment reminders and recalls through scheduling, bill pay, prescription refills, broadcast messaging, discharge instructions and post discharge symptom check ins. Not tied to a clinical specialty. Geography is the United States. Held at B rather than A because none of the breadth is evidenced by a named deployment.